TrialBritish journal of haematology2025

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Charles Herbaux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.